<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32576912</PMID><DateCompleted><Year>2020</Year><Month>11</Month><Day>30</Day></DateCompleted><DateRevised><Year>2021</Year><Month>06</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Jun</Month><Day>23</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>10175</StartPage><MedlinePgn>10175</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10175</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-020-67138-8</ELocationID><Abstract><AbstractText>Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease leading to progressive and irreversible muscle atrophy. The diagnosis of ALS is time-consuming and complex, with the clinical and neurophysiological evaluation accompanied by monitoring of progression and a long procedure for the discrimination of similar neurodegenerative diseases. The delayed diagnosis strongly slows the potential development of adequate therapies and the time frame for a prompt intervention. The discovery of new biomarkers could improve the disease diagnosis, as well as the therapeutic and rehabilitative effectiveness and monitoring of the pathological progression. In this work saliva collected from 19 patients with ALS, 10 affected by Parkinson's disease, 10 affected by Alzheimer's disease and 10 healthy subjects, was analysed using Raman spectroscopy, optimizing the parameters for detailed and reproducible spectra. The statistical multivariate analysis of the data revealed a significant difference between the groups, allowing the discrimination of the disease onset. Correlation of Raman data revealed a direct relationship with paraclinical scores, identifying multifactorial biochemical modifications related to the pathology. The proposed approach showed a promising accuracy in ALS onset discrimination, using a fast and sensitive procedure that can make more efficient the diagnostic procedure and the monitoring of therapeutic and rehabilitative processes in ALS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carlomagno</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banfi</LastName><ForeName>P I</ForeName><Initials>PI</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gualerzi</LastName><ForeName>A</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-2996-5714</Identifier><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Picciolini</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volpato</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychology, Universit&#xe0; Cattolica del Sacro Cuore, Milan, 20123, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meloni</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lax</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colombo</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Istituto Auxologico Italiano, IRCCS Department of Neurology and Laboratory of Neuroscience, 20149, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Universit&#xe0; degli Studi di Milano, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ticozzi</LastName><ForeName>N</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5963-7426</Identifier><AffiliationInfo><Affiliation>Istituto Auxologico Italiano, IRCCS Department of Neurology and Laboratory of Neuroscience, 20149, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Universit&#xe0; degli Studi di Milano, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verde</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Istituto Auxologico Italiano, IRCCS Department of Neurology and Laboratory of Neuroscience, 20149, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>V</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-7698-3854</Identifier><AffiliationInfo><Affiliation>Istituto Auxologico Italiano, IRCCS Department of Neurology and Laboratory of Neuroscience, 20149, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Universit&#xe0; degli Studi di Milano, 20122, Milan, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>"Aldo Ravelli" Center for Neurotechnology and Experimental Brain Therapeutics, Universit&#xe0; degli Studi di Milano, 20122, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bedoni</LastName><ForeName>M</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2618-3661</Identifier><AffiliationInfo><Affiliation>IRCCS Fondazione Don Carlo Gnocchi, Milan, 20148, Italy. mbedoni@dongnocchi.it.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>06</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012463" MajorTopicYN="N">Saliva</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare that they have no competing interests. Dr. Silani is in the Editorial Board of Amyotrophic Lateral Sclerosis, European Neurology, American Journal of Neurodegenerative Diseases, Frontiers in Neurology; received compensation for consulting services and/or speaking activities from AveXis, Cytokinetics, Italfarmaco, and Zambon.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>6</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32576912</ArticleId><ArticleId IdType="pmc">PMC7311476</ArticleId><ArticleId IdType="doi">10.1038/s41598-020-67138-8</ArticleId><ArticleId IdType="pii">10.1038/s41598-020-67138-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Elamin M, et al. Predicting prognosis in amyotrophic lateral sclerosis: a simple algorithm. J. Neurol. 2015;262:1447&#x2013;1454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469087</ArticleId><ArticleId IdType="pubmed">25860344</ArticleId></ArticleIdList></Reference><Reference><Citation>Oskarsson B, Gendron TF, Staff NP. Amyotrophic Lateral Sclerosis: An Update for 2018. Mayo Clin. Proc. 2018;93:1617&#x2013;1628.</Citation><ArticleIdList><ArticleId IdType="pubmed">30401437</ArticleId></ArticleIdList></Reference><Reference><Citation>Marin B, et al. Variation in worldwide incidence of amyotrophic lateral sclerosis: a meta-analysis. Int. J. Epidemiol. 2016;46:dyw061.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5407171</ArticleId><ArticleId IdType="pubmed">27185810</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic Lateral Sclerosis. N. Engl. J. Med. 2017;377:162&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner MR, Benatar M. Ensuring continued progress in biomarkers for amyotrophic lateral sclerosis. Muscle Nerve. 2015;51:14&#x2013;18.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4270289</ArticleId><ArticleId IdType="pubmed">25288265</ArticleId></ArticleIdList></Reference><Reference><Citation>Valadi N. Evaluation and Management of Amyotrophic Lateral Sclerosis. Prim. Care - Clin. Off. Pract. 2015;42:177&#x2013;187.</Citation><ArticleIdList><ArticleId IdType="pubmed">25979579</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu LT, Bowser R. Fluid-Based Biomarkers for Amyotrophic Lateral Sclerosis. Neurotherapeutics. 2017;14:119&#x2013;134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5233638</ArticleId><ArticleId IdType="pubmed">27933485</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, et al. Neurofilament levels as biomarkers in asymptomatic and symptomatic familial amyotrophic lateral sclerosis. Ann. Neurol. 2016;79:152&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">26528863</ArticleId></ArticleIdList></Reference><Reference><Citation>De Felice B, et al. miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics. 2014;15:243&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">25130371</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson ME, Boumaza I, Lacomis D, Bowser R. Cystatin C: A Candidate Biomarker for Amyotrophic Lateral Sclerosis. PLoS One. 2010;5:e15133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3000338</ArticleId><ArticleId IdType="pubmed">21151566</ArticleId></ArticleIdList></Reference><Reference><Citation>Freischmidt A, M&#xfc;ller K, Ludolph AC, Weishaupt JH. Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 2013;1:42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3893596</ArticleId><ArticleId IdType="pubmed">24252274</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams KL, et al. Pathophysiological insights into ALS with C9ORF72 expansions. J. Neurol. Neurosurg. Psychiatry. 2013;84:931&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">23463871</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J. Rare Dis. 2009;4:3.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2656493</ArticleId><ArticleId IdType="pubmed">19192301</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IRA, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis withSOD1 mutations. Ann. Neurol. 2007;61:427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen S, Sayana P, Zhang X, Le W. Genetics of amyotrophic lateral sclerosis: an update. Mol. Neurodegener. 2013;8:28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3766231</ArticleId><ArticleId IdType="pubmed">23941283</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosengren LE, Karlsson J-E, Karlsson J-O, Persson LI, Wikkels&#xf8; C. Patients with Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases Have Increased Levels of Neurofilament Protein in CSF. J. Neurochem. 2002;67:2013&#x2013;2018.</Citation><ArticleIdList><ArticleId IdType="pubmed">8863508</ArticleId></ArticleIdList></Reference><Reference><Citation>Boylan KB, et al. Phosphorylated neurofilament heavy subunit (pNF-H) in peripheral blood and CSF as a potential prognostic biomarker in Amyotrophic Lateral Sclerosis. J. Neurol. Neurosurg. Psychiatry. 2013;84:467&#x2013;472.</Citation><ArticleIdList><ArticleId IdType="pubmed">23117489</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu C-HCH, et al. Neurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis. Neurology. 2015;84:2247&#x2013;2257.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4456658</ArticleId><ArticleId IdType="pubmed">25934855</ArticleId></ArticleIdList></Reference><Reference><Citation>CHEN Y, et al. Proteomic analysis of cerebrospinal fluid in amyotrophic lateral sclerosis. Exp. Ther. Med. 2016;11:2095&#x2013;2106.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4887813</ArticleId><ArticleId IdType="pubmed">27284291</ArticleId></ArticleIdList></Reference><Reference><Citation>Vucic, S. &amp; Rutkove, S. B. Neurophysiological biomarkers in amyotrophic lateral sclerosis. Curr. Opin. Neurol. 1, 10.1097/WCO.0000000000000593 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30080715</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiappin S, Antonelli G, Gatti R, De Palo EF. Saliva specimen: A new laboratory tool for diagnostic and basic investigation. Clin. Chim. Acta. 2007;383:30&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">17512510</ArticleId></ArticleIdList></Reference><Reference><Citation>Bermejo-Pareja F, Antequera D, Vargas T, Molina JA, Carro E. Saliva levels of Abeta1-42 as potential biomarker of Alzheimer&#x2019;s disease: a pilot study. BMC Neurol. 2010;10:108.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2987856</ArticleId><ArticleId IdType="pubmed">21047401</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller CS, King CP, Langub MC, Kryscio RJ, Thomas MV. Salivary biomarkers of existing periodontal disease: A cross-sectional study. J. Am. Dent. Assoc. 2006;137:322&#x2013;329.</Citation><ArticleIdList><ArticleId IdType="pubmed">16570465</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao PV, et al. Proteomic Identification of Salivary Biomarkers of Type-2 Diabetes. J. Proteome Res. 2009;8:239&#x2013;245.</Citation><ArticleIdList><ArticleId IdType="pubmed">19118452</ArticleId></ArticleIdList></Reference><Reference><Citation>Terada K, et al. Prevalence of serum and salivary antibodies to HTLV-1 in Sj&#xf6;gren&#x2019;s syndrome. Lancet. 1994;344:1116&#x2013;1119.</Citation><ArticleIdList><ArticleId IdType="pubmed">7934493</ArticleId></ArticleIdList></Reference><Reference><Citation>In, A. et al. Saliva as a diagnostic medium. 153, 103&#x2013;110 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19771133</ArticleId></ArticleIdList></Reference><Reference><Citation>Tumilasci OR, et al. Quantitative study of salivary secretion in Parkinson&#x2019;s disease. Mov. Disord. 2006;21:660&#x2013;667.</Citation><ArticleIdList><ArticleId IdType="pubmed">16419045</ArticleId></ArticleIdList></Reference><Reference><Citation>Obayashi K, et al. Salivary chromogranin A: useful and quantitative biochemical marker of affective state in patients with amyotrophic lateral sclerosis. Intern. Med. 2008;47:1875&#x2013;1879.</Citation><ArticleIdList><ArticleId IdType="pubmed">18981630</ArticleId></ArticleIdList></Reference><Reference><Citation>Roozendaal B, et al. The cortisol awakening response in amyotrophic lateral sclerosis is blunted and correlates with clinical status and depressive mood. Psychoneuroendocrinology. 2012;37:20&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">21616601</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng, S. et al. Surface-enhanced Raman spectroscopy of saliva proteins for the noninvasive differentiation of benign and malignant breast tumors. Int. J. Nanomedicine 537, 10.2147/IJN.S71811 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4298339</ArticleId><ArticleId IdType="pubmed">25609959</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Arteaga A, et al. Diagnosis of breast cancer by analysis of sialic acid concentrations in human saliva by surface-enhanced Raman spectroscopy of silver nanoparticles. Nano Res. 2017;10:3662&#x2013;3670.</Citation></Reference><Reference><Citation>Harris AT, et al. Raman spectroscopy in head and neck cancer. Head Neck Oncol. 2010;2:26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2958871</ArticleId><ArticleId IdType="pubmed">20923567</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanna R, et al. Label-free imaging and identification of typical cells of acute myeloid leukaemia and myelodysplastic syndrome by Raman microspectroscopy. Analyst. 2015;140:1054&#x2013;1064.</Citation><ArticleIdList><ArticleId IdType="pubmed">25568900</ArticleId></ArticleIdList></Reference><Reference><Citation>Chisanga M, et al. Enhancing Disease Diagnosis: Biomedical Applications of Surface-Enhanced Raman Scattering. Appl. Sci. 2019;9:1163.</Citation></Reference><Reference><Citation>Lieber CA, Majumder SK, Ellis DL, Billheimer DD, Mahadevan-Jansen A. In vivo nonmelanoma skin cancer diagnosis using Raman microspectroscopy. Lasers Surg. Med. 2008;40:461&#x2013;467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2782422</ArticleId><ArticleId IdType="pubmed">18727020</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryzhikova E, et al. Raman spectroscopy of blood serum for Alzheimer&#x2019;s disease diagnostics: specificity relative to other types of dementia. J. Biophotonics. 2015;8:584&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4575592</ArticleId><ArticleId IdType="pubmed">25256347</ArticleId></ArticleIdList></Reference><Reference><Citation>Paraskevaidi M, Martin-Hirsch PL, Martin FL. Vibrational spectroscopy: a promising approach to discriminate neurodegenerative disorders. Mol. Neurodegener. 2018;13:20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5930438</ArticleId><ArticleId IdType="pubmed">29716629</ArticleId></ArticleIdList></Reference><Reference><Citation>Farquharson S, Shende C, Inscore FE, Maksymiuk P, Gift A. Analysis of 5-fluorouracil in saliva using surface-enhanced Raman spectroscopy. J. Raman Spectrosc. 2005;36:208&#x2013;212.</Citation></Reference><Reference><Citation>Li X, Yang T, Lin J. Spectral analysis of human saliva for detection of lung cancer using surface-enhanced Raman spectroscopy. J. Biomed. Opt. 2012;17:037003.</Citation><ArticleIdList><ArticleId IdType="pubmed">22502575</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonifacio A, et al. Surface-enhanced Raman spectroscopy of blood plasma and serum using Ag and Au nanoparticles: a systematic study. Anal. Bioanal. Chem. 2014;406:2355&#x2013;2365.</Citation><ArticleIdList><ArticleId IdType="pubmed">24493335</ArticleId></ArticleIdList></Reference><Reference><Citation>Misra AK, et al. Near-Infrared Micro-Raman Spectroscopy for in Vitro Detection of Cervical Cancer. Appl. Spectrosc. Vol. 64, Issue 3, pp. 255-261. 2010;64:255&#x2013;261.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2880181</ArticleId><ArticleId IdType="pubmed">20223058</ArticleId></ArticleIdList></Reference><Reference><Citation>by Dove Press, published. IJN-71811-saliva-proteins-surface-enhanced-raman-spectroscopy-for-non-., 10.2147/IJN.S71811 (2015).</Citation></Reference><Reference><Citation>Ringn&#xe9;r M. What is principal component analysis? Nat. Biotechnol. 2008;26:303&#x2013;304.</Citation><ArticleIdList><ArticleId IdType="pubmed">18327243</ArticleId></ArticleIdList></Reference><Reference><Citation>Devitt G, Howard K, Mudher A, Mahajan S. Raman Spectroscopy: An Emerging Tool in Neurodegenerative Disease Research and Diagnosis. ACS Chem. Neurosci. 2018;9:404&#x2013;420.</Citation><ArticleIdList><ArticleId IdType="pubmed">29308873</ArticleId></ArticleIdList></Reference><Reference><Citation>Virkler K, Lednev IK. Forensic body fluid identification: The Raman spectroscopic signature of saliva. Analyst. 2010;135:512&#x2013;517.</Citation><ArticleIdList><ArticleId IdType="pubmed">20174703</ArticleId></ArticleIdList></Reference><Reference><Citation>Adibhatla RM, Hatcher JF. Altered lipid metabolism in brain injury and disorders. Subcell. Biochem. 2008;49:241&#x2013;268.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2293298</ArticleId><ArticleId IdType="pubmed">18751914</ArticleId></ArticleIdList></Reference><Reference><Citation>Reed TT. Lipid peroxidation and neurodegenerative disease. Free Radical Biology and Medicine. 2011;51:1302&#x2013;1319.</Citation><ArticleIdList><ArticleId IdType="pubmed">21782935</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann. Neurol. 2002;52:448&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">12325074</ArticleId></ArticleIdList></Reference><Reference><Citation>Doria M, Maugest L, Moreau T, Lizard G, Vejux A. Contribution of cholesterol and oxysterols to the pathophysiology of Parkinson&#x2019;s disease. Free Radical Biology and Medicine. 2016;101:393&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">27836779</ArticleId></ArticleIdList></Reference><Reference><Citation>Cutler RG, Pedersen WA, Camandola S, Rothstein JD, Mattson MP. Evidence that accumulation of ceramides and cholesterol esters mediates oxidative stress-induced death of motor neurons in amyotrophic lateral sclerosis. Ann. Neurol. 2002;52:448&#x2013;457.</Citation><ArticleIdList><ArticleId IdType="pubmed">12325074</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X, et al. Lower low-density lipoprotein cholesterol levels are associated with Parkinson&#x2019;s disease. Mov. Disord. 2007;22:377&#x2013;381.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1906875</ArticleId><ArticleId IdType="pubmed">17177184</ArticleId></ArticleIdList></Reference><Reference><Citation>Shepardson NE. Cholesterol Level and Statin Use in Alzheimer Disease. Arch. Neurol. 2011;68:1239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3211071</ArticleId><ArticleId IdType="pubmed">21987540</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagey R, Pelech SL, Duronio V, Krieger C. Phosphatidylinositol 3-Kinase: Increased Activity and Protein Level in Amyotrophic Lateral Sclerosis. J. Neurochem. 2002;71:716&#x2013;722.</Citation><ArticleIdList><ArticleId IdType="pubmed">9681462</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma MW, et al. NADPH oxidase in brain injury and neurodegenerative disorders. Mol. Neurodegener. 2017;12:7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5240251</ArticleId><ArticleId IdType="pubmed">28095923</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradat P-F, et al. Impaired glucose tolerance in patients with amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. 2010;11:166&#x2013;171.</Citation><ArticleIdList><ArticleId IdType="pubmed">20184518</ArticleId></ArticleIdList></Reference><Reference><Citation>LIU D, WEN J, LIU J, LI L. The roles of free radicals in amyotrophic lateral sclerosis: reactive oxygen species and elevated oxidation of protein, DNA, and membrane phospholipids. FASEB J. 1999;13:2318&#x2013;2328.</Citation><ArticleIdList><ArticleId IdType="pubmed">10593879</ArticleId></ArticleIdList></Reference><Reference><Citation>Cedarbaum JM, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J. Neurol. Sci. 1999;169:13&#x2013;21.</Citation><ArticleIdList><ArticleId IdType="pubmed">10540002</ArticleId></ArticleIdList></Reference><Reference><Citation>Desport J-C, Torny F, Lacoste M, Preux P-M, Couratier P. Hypermetabolism in ALS: Correlations with Clinical and Paraclinical Parameters. Neurodegener. Dis. 2005;2:202&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">16909026</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Berg LH, et al. Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology. 2019;92:e1610&#x2013;e1623.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6448453</ArticleId><ArticleId IdType="pubmed">30850440</ArticleId></ArticleIdList></Reference><Reference><Citation>Obayashi K. Salivary mental stress proteins. Clin. Chim. Acta. 2013;425:196&#x2013;201.</Citation><ArticleIdList><ArticleId IdType="pubmed">23939251</ArticleId></ArticleIdList></Reference><Reference><Citation>Poletti B, et al. The validation of the Italian Edinburgh Cognitive and Behavioural ALS Screen (ECAS) Amyotroph. Lateral Scler. Front. Degener. 2016;17:489&#x2013;498.</Citation><ArticleIdList><ArticleId IdType="pubmed">27219526</ArticleId></ArticleIdList></Reference><Reference><Citation>Burkhardt C, Neuwirth C, Weber M. Longitudinal assessment of the Edinburgh Cognitive and Behavioural Amyotrophic Lateral Sclerosis Screen (ECAS): lack of practice effect in ALS patients? Amyotroph. Lateral Scler. Front. Degener. 2017;18:202&#x2013;209.</Citation><ArticleIdList><ArticleId IdType="pubmed">28165766</ArticleId></ArticleIdList></Reference><Reference><Citation>FRENS G. Controlled Nucleation for the Regulation of the Particle Size in Monodisperse Gold Suspensions. Nat. Phys. Sci. 1973;241:20&#x2013;22.</Citation></Reference><Reference><Citation>Lee PC, Meisel D. Adsorption and surface-enhanced Raman of dyes on silver and gold sols. J. Phys. Chem. 1982;86:3391&#x2013;3395.</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2000;1:293&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Muro CK, de Souza Fernandes L, Lednev IK. Sex Determination Based on Raman Spectroscopy of Saliva Traces for Forensic Purposes. Anal. Chem. 2016;88:12489&#x2013;12493.</Citation><ArticleIdList><ArticleId IdType="pubmed">28193029</ArticleId></ArticleIdList></Reference><Reference><Citation>Postuma RB, et al. MDS clinical diagnostic criteria for Parkinson&#x2019;s disease. Mov. Disord. 2015;30:1591&#x2013;1601.</Citation><ArticleIdList><ArticleId IdType="pubmed">26474316</ArticleId></ArticleIdList></Reference><Reference><Citation>McKhann GM, et al. The diagnosis of dementia due to Alzheimer&#x2019;s disease: Recommendations from the National Institute on Aging-Alzheimer&#x2019;s Association workgroups on diagnostic guidelines for Alzheimer&#x2019;s disease. Alzheimer&#x2019;s Dement. 2011;7:263&#x2013;269.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312024</ArticleId><ArticleId IdType="pubmed">21514250</ArticleId></ArticleIdList></Reference><Reference><Citation>Albert, M. S.&#xa0;et al. The Diagnosis of Mild Cognitive Impairment Due to Alzheimer's Disease: Recommendations From the National Institute on Aging-Alzheimer's Association Workgroups on Diagnostic Guidelines for Alzheimer's Disease.&#xa0;Alzheimer&#x2019;s Dement7, 270&#x2013;279 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312027</ArticleId><ArticleId IdType="pubmed">21514249</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neil KH, Purdy M, Falk J, Gallo L. The Dysphagia Outcome and Severity Scale. Dysphagia. 1999;14:139&#x2013;145.</Citation><ArticleIdList><ArticleId IdType="pubmed">10341109</ArticleId></ArticleIdList></Reference><Reference><Citation>Kidney D, Alexander M, Corr B, O&#x2019;Toole O, Hardiman O. Oropharyngeal dysphagia in amyotrophic lateral sclerosis: neurological and dysphagia specific rating scales. Amyotroph. Lateral Scler. Other Mot. Neuron Disord. 2004;5:150&#x2013;153.</Citation><ArticleIdList><ArticleId IdType="pubmed">15512903</ArticleId></ArticleIdList></Reference><Reference><Citation>WHOQOL GROUP THE. Development of the World Health Organization WHOQOL-BREF Quality of Life Assessment. Psychol. Med. 1998;28:551&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pubmed">9626712</ArticleId></ArticleIdList></Reference><Reference><Citation>Skevington SM, Lotfy M, O&#x2019;Connell KA, WHOQOL Group The World Health Organization&#x2019;s WHOQOL-BREF quality of life assessment: Psychometric properties and results of the international field trial. A Report from the WHOQOL Group. Qual. Life Res. 2004;13:299&#x2013;310.</Citation><ArticleIdList><ArticleId IdType="pubmed">15085902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gualerzi A, et al. Raman spectroscopy uncovers biochemical tissue-related features of extracellular vesicles from mesenchymal stromal cells. Sci. Rep. 2017;7:9820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5575260</ArticleId><ArticleId IdType="pubmed">28852131</ArticleId></ArticleIdList></Reference><Reference><Citation>Movasaghi Z, Rehman S, Rehman IU. Raman Spectroscopy of Biological Tissues. Appl. Spectrosc. Rev. 2007;42:493&#x2013;541.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>